Skip To Main Content
Cost Optimisation on Muck Rack

Cost Optimisation

As seen in: Moneycontrol, Sharenet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Cost Optimisation’s profile

Articles by Cost Optimisation

GOLD FIELDS LIMITED - Operational update for the quarter ended 31 March 2026

|
By Cost Optimisation, Granny Smith, Silver Recoveries
| Sharenet
Consensus estimates are based on estimates collected by Sharenet and are calculated by taking the arithmetic average of the constituent analyst forecasts. Consensus estimates data are based on "SELL-SIDE" analysts' opinions, projections, and predictions regarding listed companies' performance. It does not represent Sharenet's own views on performance.
Open in Who Shared View Duplicates (140) Issue with article?

BTI - BRITISH AMERICAN TOBACCO PLC - Preliminary results for the year ended 31 December 2024 - 13/02/2025

|
By Cost Optimisation, Bridgwater Road, Tadeu Marroco
| Sharenet
Preliminary results for the year ended 31 December 2024 British American Tobacco p.l.c. Incorporated in England and Wales (Registration number: 03407696) Short name: BATS Share code: BTI ISIN number: GB0002875804 ("British American Tobacco p.l.c." or "the Company") 13 February 2025 - Press Release/Preliminary Results British American Tobacco p.l.c. Preliminary results for the year ended 31 December 2024 Building a Smokeless World Tadeu Marroco, Chief Executive "We are committed to Building a...
Open in Who Shared View Duplicates (5) Issue with article?

Lupin Q4 Net Profit Grows 18.2% Led By Cost Optimisation, India Sales Growth Original

|
By Viswanath Pilla Verified, Cost Optimisation
| Moneycontrol Verified
The company reported a net profit of Rs 460.4 crore in the quarter-ended March 31, but the revenue dropped by 1.6 percent YoY to Rs 3,783 crore Lupin | Company received approval from USFDA for Sulfamethoxazole and Trimethoprim Oral Suspension, which is used to treat bacterial infections. Drugmaker Lupin net profit (profit after tax) grew 18.2 percent year-on-year (YoY) to Rs 460.4 crore in the quarter ended March 31 led by cost optimisation and growth in India and other emerging markets.
Open in Who Shared View Duplicates (2) Issue with article?
Show More